Research Topics
| Asad UmarSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Chemoprevention of colorectal carcinogenesisAsad Umar
Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
Int J Clin Oncol 7:2-26. 2002..These targets will help identify more effective and better tolerated preventive agents. Carcinogenesis is now recognized as a disease in itself and has become the target of an ever-expanding array of preventive interventions...- The role of cyclooxygenase inhibitors in cancer preventionWilliam F Anderson
Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Room 2141, 6130 Executive Boulevard, Bethesda, MD 20892-7317, USA
Curr Pharm Des 8:1035-62. 2002..Nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) -1 and -2 are among the most promising classes of agents for targeted molecular prevention... - Applications of bioinformatics in cancer detection: a lexicon of bioinformatics termsAsad Umar
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
Ann N Y Acad Sci 1020:263-76. 2004..This paper compiles a list of numerous bioinformatics terms for the Applications of Bioinformatics in Cancer Detection conference. It should be helpful as a lexicon for the volume as a whole... 
Future directions in cancer preventionAsad Umar
National Cancer Institute, Division of Cancer Prevention, Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Executive Plaza North 2142, 6130 Executive Boulevard, MSC 7317, Rockville, Maryland 20852 7371, USA
Nat Rev Cancer 12:835-48. 2012....- Testing guidelines for hereditary non-polyposis colorectal cancerAsad Umar
Division of Cancer Prevention and Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Nat Rev Cancer 4:153-8. 2004 
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instabilityAsad Umar
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
J Natl Cancer Inst 96:261-8. 2004....- Lynch syndrome (HNPCC) and microsatellite instability analysis guidelinesAsad Umar
Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd, Rockville, MD 20852, USA
Cancer Biomark 2:1-4. 2006 - Development of COX inhibitors in cancer prevention and therapyAsad Umar
Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland 20892-7317, USA
Am J Clin Oncol 26:S48-57. 2003..Discovering how to apply NSAIDs in persons with-or at risk for-cancer, although challenging, has the potential for considerable clinical and public health benefits... - Gene expression analysis of tumor infiltrating lymphocyte markers in endometrial cancers indicates no significant increases in those cases with microsatellite instabilityJohn I Risinger
Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Cancer Biomark 2:61-8. 2006..These data indicate that significant differences in TIL derived transcripts do not occur between endometrioid endometrial cancers with and without microsatellite instability... - Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trialsErnest T Hawk
Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, MD, USA
Prog Exp Tumor Res 37:210-42. 2003 - Cyclooxygenase inhibition in cancer prevention and treatmentWilliam F Anderson
Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, EPN, Room 2141, 6130 Executive Boulevard, Bethesda, MD 20892-7317, USA
Expert Opin Pharmacother 4:2193-204. 2003..A brief discussion on the pharmacoeconomic considerations of NSAID and COXIB use and safety issues that have recently been the focus of debate, will be presented... - Colorectal cancer chemoprevention--an overview of the scienceErnest T Hawk
Gastrointentinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute NIH, EPN Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
Gastroenterology 126:1423-47. 2004..Innovative research models include the nesting of prevention end points within cancer treatment trials and within trials testing promising preventive compounds intended for nononcologic indications... - Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer preventionErnest T Hawk
National Cancer Institute, Division of Cancer Prevention, Bethesda, MD 20892-7317, USA
Cancer Chemother Biol Response Modif 21:759-89. 2003 - Early detection and risk assessment: proceedings and recommendations from the Workshop on Epigenetics in Cancer PreventionMukesh Verma
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20852, USA
Ann N Y Acad Sci 983:298-319. 2003..Further research will lead to the identification of new targets for cancer prevention... - Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signalingJohn I Risinger
Laboratory of Biosystems and Cancer, National Cancer Institute, Bethesda, Maryland, USA
Cancer Res 65:5031-7. 2005..These data classify histologically similar endometrioid endometrial cancers into two distinct groupings with implications affecting therapy and prevention... - Chemoprevention of colorectal cancer: problems, progress, and prospectsJaye L Viner
Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892-7317, USA
Gastroenterol Clin North Am 31:971-99. 2002..The number of trials that are investigating chemopreventives against CR neoplasia is relatively small; if these agents live up to a fraction of their promise, the public health impact may be great (see Table 6)... - Can animal models help us select specific compounds for cancer prevention trials?Ernest T Hawk
GI and Other Cancers Research Group, National Cancer Institute, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
Recent Results Cancer Res 166:71-87. 2005.... - Lynch syndrome (HNPCC) and microsatellite instabilityAsad Umar
Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892-7317, USA
Dis Markers 20:179-80. 2004 - Prevention and therapy of colorectal cancerErnest T Hawk
Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
Med Clin North Am 89:85-110, viii. 2005..These advances substantiate target-driven approaches to cancer prevention and treatment, and provide fruitful opportunities for future investigations... - One year recurrence of aberrant crypt fociPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
Cancer Prev Res (Phila) 3:839-43. 2010..After removal of ACF at baseline, ACF counts 1 year later were only slightly reduced and were significantly correlated with the baseline ACF count. The results of this study do not support a role for ACF in clinical practice... - Epigenetics in cancer prevention: early detection and risk assessment: introductionBarbara K Dunn
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Executive Plaza North, Rockville, Maryland 20852-7362, USA
Ann N Y Acad Sci 983:1-4. 2003 - The promise of biomarkers in colorectal cancer detectionAsad Umar
Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd-EPN 2143, Rockville, MD 20852, USA
Dis Markers 20:87-96. 2004 - Further thoughts on preclinical animal models for cancer prevention: when is it best to start treatment? What are potential histopathologic endpoints?Asad Umar
Division of Cancer Prevention, Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Bethesda, MD, USA
Semin Oncol 37:339-44. 2010.... - DNA methylation as a cancer-specific biomarker: from molecules to populationsArti Patel
Cancer Prevention Fellowship Program, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
Ann N Y Acad Sci 983:286-97. 2003.... - Proceedings: the Applications of Bioinformatics in Cancer Detection WorkshopIzet M Kapetanovic
Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7322, USA
Ann N Y Acad Sci 1020:1-9. 2004..This paper summarizes the proceedings of this conference and points out future directions for research... - Colorectal carcinoma in black and white raceWilliam F Anderson
National Cancer Institute/Division of Cancer Prevention/Gastrointestinal Cancer and Other Cancers Research Group, Bethesda, Maryland, USA
Cancer Metastasis Rev 22:67-82. 2003..Racial variations demonstrate the need for a more comprehensive understanding of colorectal carcinogenesis, epidemiology, and colorectal screening patterns for low- and high-risk populations... - Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumorsMichael A Pereira
Department of Pathology, Medical College of Ohio, Toledo, OH 43614, USA
Carcinogenesis 25:1917-23. 2004..Celecoxib and DFMO reversed DNA hypomethylation and the hypermethylation of the ER-alpha gene in colon tumors supporting the hypothesis that modulation of methylation is a biomarker of chemoprevention... - Serum proteomic profiles suggest celecoxib-modulated targets and response predictorsZhen Xiao
Laboratory of Proteomics and Analytical Technologies and Advanced Biomedical Computing Center, SAIC-Frederick Inc, National Cancer Institute at Frederick, Frederick, Maryland, USA
Cancer Res 64:2904-9. 2004..In particular, a spectral feature at m/z 16,961.4 was identified as a strong discriminator between response and nonresponse to celecoxib at the highest dose... - An Msh2 point mutation uncouples DNA mismatch repair and apoptosisDiana P Lin
Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York, USA
Cancer Res 64:517-22. 2004.... - The natural history of aberrant crypt fociRobert E Schoen
University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Gastrointest Endosc 67:1097-102. 2008..Aberrant crypt foci (ACF) are the putative precursors to colorectal adenomas and may be useful as biomarkers. Knowledge of their natural history is essential to understanding their potential utility... - Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitorsQiang Lu
Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
J Med Chem 47:467-74. 2004....